SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- AnaptysBio,
Inc., a privately-held therapeutic antibody company, today
announced the publication of a novel full-length antibody scaffold,
applicable to the development of highly thermostable antibodies for
therapeutic and diagnostic applications, in the journal of Protein
Engineering, Design & Selection (PEDS).
(Logo:
http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)
Entitled "An integrated approach to extreme thermostabilization
and affinity maturation of an antibody", Dr. David J. King, chief scientific officer of
AnaptysBio, and his team describe a novel IgG scaffold that
maintains high binding affinity to its target antigen despite
exposure to high temperature conditions for extended periods.
Accelerated stability data indicates that antibodies
generated using this technology would remain stable at room
temperature for several years.
To date, this novel approach has been successfully utilized by
AnaptysBio to generate highly stable antibodies against multiple
antigens. As demonstrated in the aforementioned publication,
existing antibodies with poor stability parameters can be
effectively transformed by AnaptysBio's SHM-XEL platform to confer
high thermal stability, while simultaneously improving binding
affinity. In addition, AnaptysBio has designed diverse
library repertoires that permit de novo discovery of high
thermostability antibodies in the context of its proprietary
SHM-XEL platform.
"To our knowledge, this publication describes the most stable
full-length antibody reported to date," said Hamza Suria, president & chief executive
officer of AnaptysBio. "Our ability to generate antibodies with
extended room temperature thermostability provides a significant
commercial advantage to future antibody-based therapeutic and
diagnostic products. Enhanced thermostability would reduce,
or even eliminate, cold chain dependency during production,
shipping and storage of antibody products. These advantages
may be particularly useful in developing countries, where the
availability of antibody products is often constrained by
dependency on refrigeration systems."
About AnaptysBio
Founded in 2005, AnaptysBio, Inc. is a privately-held company
focused on the generation of antibody therapeutics, and the leader
in the use of somatic hypermutation (SHM) for antibody discovery
and optimization. AnaptysBio's proprietary SHM-XEL platform, which
couples fully human antibody libraries with in vitro somatic
hypermutation (SHM) in mammalian cells to generate high affinity
lead candidates, replicates key features of the human immune system
and overcomes limitations of prior antibody technologies. By
harnessing the natural mechanism of antibody maturation under
controlled conditions, SHM-XEL allows for the selection of optimal
antibody properties such as high affinity, function,
cross-reactivity, epitope diversity and
manufacturability. AnaptysBio has established broad
intellectual property around the use of SHM and is currently
building a pipeline of novel therapeutic antibody product
candidates, including differentiated programs in cancer
immunotherapy, inflammation, muscle wasting disorders and
antibody-drug conjugate applications. The Company has previously
announced pharma partnerships with Merck, Roche, Novartis, Celgene
and Gilead. Major investors in AnaptysBio include Alloy
Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo
A/S. For more information, visit www.anaptysbio.com.
SOURCE AnaptysBio, Inc.